Profile

Mark R. Emmett, PhD
Mark R. Emmett, PhD
Cancer Pharmacology
Read Bio

  • Professor,
    Department of Biochemistry and Molecular Biology

    Phone: (409) 747-1943
    Fax: (409) 747-1938
    Email:mremmett@utmb.edu
  • Dr. Emmett's work seeks to identify novel therapeutic targets and biomarkers in neuro-oncology by utilizing high-resolution, high sensitivity mass spectrometry (FT-ICR MS). His group uses  a multi-disciplinary systems approach that integrates genomics, transcriptomics, proteomics, glycomics, lipidomics, metabolomics, and phenotypic responses with computational data analysis to the study of cancer, with the identification of novel biomarkers and therapeutic targets as the primary goals.
    1. Proteomic Investigation of Glioblastoma Cell Lines Treated with Wild-Type p53 and Cytotoxic Chemotherapy Demonstrates an Association between Galectin-1 and p53 Expression, Maja Puchades, Carol L. Nilsson, Mark R. Emmett, Kenneth D. Aldape, Yongjie Ji, Frederick F. Land, Ta-Jen Liu, and Charles A. Conrad, Journal of Proteome Research, 2007, 6: 869-875.
    2. Method for Lipidomic Analysis: p53 Expression Modulation of Sulfatide, Ganglioside and Phospholipid Composition of U87 MG Glioblastoma Cells, Huan He, Charles A. Conrad, Carol L. Nilsson, Yongjie Ji, Tanner M. Schaub, Alan G. Marshall and Mark R. Emmett, Analytical Chemistry, 2007, 79: 8423-8430.
    3. KIT Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients, Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M.; He, Y.-A.; Jacques, S. L.; Lunney, E. A.; McTigue, M; Molina, D.; Quenzer, T. A.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H.-M.; Demetri, G. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1542-1547.
    4. Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, Irinotecan, Huan He, Carol L. Nilsson, Mark R. Emmett, Yongjie Ji, Alan G. Marshall, Roger A. Kroes, Joseph R. Moskal, Howard Colman, Frederick F. Lang, and Charles A. Conrad, Glycoconjugates. 2010, 27(1): 27-38.
    5. Glycomic and transcriptomic response of GSC-11 glioblastoma stem cells to STAT-3 phosphorylation inhibition and serum-induced differentiation, Huan He, Carol L. Nilsson, Mark R. Emmett, Alan G. Marshall, Roger A. Kroes, Joseph R. Moskal, Yongjie Ji, Howard Colman, Waldemar Priebe, Frederick F. Lang, and Charles A. Conrad, J. Proteomics Research, 2010, 9: 2098-2108.
    6. Overexpression of ST6GalNAcV, a ganglioside-specific a2,6 sialyltransferase, inhibits glioma invasivity. Roger A. Kroes, Huan He, Mark R. Emmett, Carol L. Nilsson, Alan G. Marshall, and Joseph R. Moskal, Proceedings of the National Academy of Sciences, 2010, 107 (28): 12646-12651.
    7. Liquid Chromatography Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometric Characterization of N-Linked Glycans and Glycopeptides, Xu Wang, Mark R. Emmett, and Alan G. Marshall, Analytical Chemistry, 2010, 82, 6542-6548.
    8. New Reagents for Enhanced Liquid Chromatographic Separation and Charging of Intact Protein Ions for Electrospray Ionization Mass Spectrometry, Santosh G. Valeja, Jeremiah D. Tipton, Mark R. Emmett and Alan G. Marshall, Analytical Chemistry, 2010, 82, 7515-7519.
    9. Computing H/D-Exchange rates of single residues from data of proteolytic fragments, Ernst Althaus, Stefan Canzar, Carsten Ehrler, Mark R. Emmett, Andres Karrenbauer, Alan G. Marshall, Anke Meyer-Baese, Jeremiah D. Tipton and Huimin Zhang, BMC Bioinformatics, 2010, 11: 424-436.
    10. Determining and interpreting correlations in lipidomic networks found in glioblastoma cells, Robert Gorke, Anke Meyer-Base, Dorothea Wagner, Huan He, Mark R. Emmett, Charles A. Conrad, BMC Systems Biology, 2010, 4: 126-139. http:www.biomedcentral.com/1752-0509/4/126.